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ABSTRACT
Allogeneic stem cell transplantation (alloSCT) has been used in the hopes of harnessing the curative potential
of the graft-versus-myeloma effect. This study examines the long-term outcomes of a large cohort of patients
with myeloma who were treated with myeloablative alloSCT at a single center. Comparisons are made with
those who were treated with autologous stem cell transplantation (ASCT). Between January 1989 and February
2002, 158 patients age <55 years underwent SCT for myeloma. Seventy-two patients underwent myeloablative
alloSCT (58 related; 14 unrelated), whereas 86 patients underwent ASCT. Most patients received single-agent
high dose dexamethasone or VAD (vincristine, adriamycin, dexamethasone) therapy pre-SCT. Conditioning
regimens were melphalan-based for all ASCT patients, whereas the alloSCT patients received melphalan-
based (70%), total-body irradiation (TBI)-based (18%), or other (13%). Patients who underwent alloSCT were
younger, had a higher Durie-Salmon stage disease, and a shorter median time from diagnosis to transplant.
Myeloma subtypes were similar between groups. Other pre-SCT (BMT) characteristics were similar except
that ASCT patients had a higher proportion of cases that received palliative radiotherapy pre-SCT. Disease
response pre-SCT was similar. At last follow-up, 61 of 158 patients are alive with a median follow-up of 88.4
months (range: 35.5-208.5). The overall survival (OS) of the alloSCT cohort was 48.1% at 5 years and 39.9%
at 10 years compared to 46.2% at 5 years and 30.8% at 10 years for the ASCT cohort (P  .94). The event-free
survival of the alloSCT cohort was 33.3% at 5 years and 31.4% at 10 years compared to 32.9% and 15.2%for
the ASCT cohort (P .64). Treatment-related mortality (TRM) at 1 year was 22% for the alloSCT cohort and
14% in the ASCT cohort (P  .21). Cumulative incidence of grade II-IV acute graft-versus-host disease
(aGVHD) was 72% and the cumulative incidence of chronic GVHD (cGVHD) was 68% at 2 years. Neither
aGVHD nor cGVHD had an influence on OS or event-free survival, although 5 of 14 patients who have
received donor lymphocyte infusions (DLI) have had disease response. The risk of relapse was reduced in those
who developed aGVHD (P  .02) but not cGVHD (P  .23). In conclusion, although there are patient who are
alive without disease >10 years post myeloablative alloSCT, similarly there are long-term survivors post-
ASCT. Myeloablative alloSCT should not be considered standard treatment, and should only be considered in
the context of a clinical trial.
© 2007 American Society for Blood and Marrow Transplantation
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nNTRODUCTION
Autologous stem cell transplantation (ASCT) is
outinely offered to eligible patients with multiple
yeloma. Although the survival beneﬁt of ASCT rompared to conventional chemotherapy is in dispute,
he relatively low morbidity and mortality rate make it
n attractive therapeutic modality [1-5]. Unfortu-
ately, for most patients, their myeloma eventually
elapse requiring further therapy.
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J. Kuruvilla et al.926Allogeneic stem cell transplantation (alloSCT) has
een utilized in the hopes of lowering relapse rates
nd increasing survival. Possible reasons for the lower
isk of relapse is the use of stem cells uncontaminated
y tumor cells and more importantly the graft-versus-
yeloma (GVM) effect [6,7]. Previous reports de-
cribing the experience of fully myeloablative alloSCT
ave limited median follow-up of survivors of 5
ears [8-12]. Because of the chronic nature of my-
loma, longer follow-up would be informative. Most
f these reports conclude that alloSCT results in re-
uced risk of relapse, which is countered by increased
reatment-related mortality (TRM). The European
one Marrow Transplantation (EBMT) Registry has
erformed a retrospective analysis showing the overall
urvival (OS) of patients who underwent myeloabla-
ive alloSCT was inferior to case-matched patients
ho underwent ASCT [13]. Similar to the other re-
orts, the poor outcome of patients receiving alloSCT
as attributed to a higher TRM but the rate of relapse
as not reduced when compared to ASCT.
SCT has been offered to patients with multiple
yeloma in Vancouver since 1989. A previous publi-
ation described our initial results [14]. This report
escribes our updated results with increased number
f patients and an extended median follow-up of sur-
iving patients of 8 years. Patients who received
lloSCT were compared to those who received ASCT
ith respect to OS and event-free survival (EFS).
irect comparison is not possible because of the ret-
ospective nature of this study and problems with
election bias, but was performed to help assess and
llustrate the limitations of myeloablative alloSCT.
ATIENTS AND METHODS
atients and Study Design
Approval from the University of British Columbia
UBC) research ethics board was obtained to retro-
pectively review patient data for this study. Patients
ere eligible for alloSCT up to age 55. Patients were
ligible for ASCT up to age 65, but only those up to
he age of 55 were included in this study to allow for
more appropriate comparison with patients who
eceived an alloSCT. Between February 1989 and
ebruary 2002, 232 patients underwent SCT for mul-
iple myeloma of whom 159 were 56 years of age at
he time of transplantation. Informed consent was
btained before proceeding to transplant. Charts and
ecords from a computerized database of all patients
ere reviewed. Seventy-two alloSCT recipients (58
elated donor and 14 unrelated donor) and 86 ASCT
ecipients were included for analysis. One patient who
eceived a syngeneic transplant was excluded. One
atient who had received an ASCT at another center
eceived an alloSCT for relapsed disease at our insti- aution. This patient is included in the alloSCT group.
o other patient received 1 transplants. All patients
ad adequate cardiac, pulmonary, hepatic, and renal
unction based upon predeﬁned criteria. Patients had
o have a serum creatinine of 200 mol/L and at
east stable disease following induction therapy to be
ligible for ASCT. Patients with progressive disease
emained eligible for alloSCT. No formal criteria
ere used in determining which patients should be
ffered alloSCT instead of ASCT. All patients were
iscussed within the physician group. In general, pa-
ients with younger age, more advanced or less re-
ponsive disease, were offered alloSCT if they were
eemed ﬁt to survive the procedure. Baseline patient
haracteristics are presented in Table 1.
nduction Therapy, Conditioning Regimens, and
tem Cell Source
Pretransplantation therapy varied based on the
ime period during which the patient was initially
ssessed for transplantation. Patients may have re-
eived melphalan-based chemotherapy prior to refer-
al to our center, although it was our recommendation
hat this be avoided. Induction therapy typically con-
isted of vincristine, doxorubicin, dexamethasone
VAD)-based [15] chemotherapy or single-agent dexa-
ethasone followed by peripheral blood stem cell
ollection (PBSC) or bone marrow harvest. Early pa-
ients were more heavily pretreated and received up to
regimens pretransplant. The strategy of utilizing
ingle-agent dexamethasone with minimal delay be-
ore proceeding to transplantation was eventually
dopted to minimize potential toxicity prior to inten-
ive therapy. All but 3 patients received high-dose
examethasone alone or in combination with VAD
rior to SCT . Radiation therapy was used for patients
ith plasmacytomas, pathologic fractures, or for pal-
iative symptom relief prior to SCT.
The conditioning regimen for both ASCT and
elated donor alloSCT typically consisted of oral
usulfan (12 mg/kg), intravenous (i.v.) melphalan (100
g/m2) and cyclophosphamide (90 mg/kg). Patients
ndergoing volunteer unrelated donor transplantation
eceived total-body irradiation (TBI) 1200 cGy given
n 6 fractions and cyclophosphamide 50 mg/kg daily
or 3 days as conditioning. There were 58 sibling
ransplants and 14 unrelated donor transplants. Stem
ell source for all alloSCT was bone marrow. Source
f autografts were purged bone marrow using either
-hydroxpercyclophosphamide (4-HC) or mafosf-
mide (n 25), and unpurged PBSC (n 61). PBSCs
ere mobilized with cyclophosphamide (2.5-7.0 g/m2)
ollowed by granulocyte colony-stimulating factor (G-
SF). Patients in the ASCT group were offered main-
enance treatment with interferon 3 million units 3
imes a week posttransplant until relapse or intoler-
nce. Fifty-eight patients agreed to receive interferon.
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Long-Term Outcome of Myeloablative AlloSCT for Multiple Myeloma 927raft-versus-Host Disease (GVHD) Prophylaxis
nd Evaluation
Only 1 patient received a T cell-depleted allograft.
he majority of patients received prophylaxis with
yclosporine and short-course methotrexate, although
everal patients received cyclosporine and methyl-
rednisolone. Acute GVHD (aGVHD) and chronic
VHD (cGVHD) were graded based on standard
able 1. Patient Characteristics Pre-SCT
Characteristic ALLO n (%) AUTO n (%) P-Value
ge
Median 44 51 <.001
range (25-54) (24-55)
ime from DX to SCT
<6 months 55 (76) 50 (58) <.01
6-12 months 5 (7) 23 (27)
>12 months 12 (17) 13 (15)
ex
Male 40 (56) 54 (63) .36
Female 32 (44) 32 (37)
-protein
G 34 (47) 50 (60) .50
A 15 (21) 16 (19)
Light chain 17 (24) 17 (20)
Nonsecretor 5 (7) 3 (3)
Other 1 (1) 0 (0)
urie-Salmon stage
I 2 (3) 9 (11) .03
II 14 (19) 27 (31)
III 56 (78) 50 (58)
enal impairment
Yes 10 (14) 11 (13) .65
No 62 (86) 74 (86)
Unknown 0 (0) 1 (1)
eta-2 microglobulin
<3.0 22 (31) 31 (36) .53
>3.0 15 (21) 22 (26)
Unavailable 35 (48) 33 (38)
COG performance
status
0 28 (39) 29 (34) .81
1 29 (41) 40 (46)
2-3 13 (18) 13 (15)
Unavailable 2 (2) 4 (5)
umber of prior
therapies
1 54 (75) 69 (80) .64
2 15 (21) 13 (15)
>3 3 (4) 4 (5)
rior radiotherapy
No 45 (63) 39 (45) .03
Yes 27 (38) 47 (55)
isease status pre-SCT
CR/VGPR 4 (5) 7 (8) .28
PR 48 (67) 64 (74)
MR/SD/PD 20 (28) 15 (18)
COG indicates Eastern Cooperative Oncology Group; CR, com-
plete response; VGPR, very good partial response; PR, partial
response; MR, minimal response; SD, stable disease; PD, pro-
gressive disease; SCT, stem cell transplantation.riteria [16,17]. aesponse Criteria
The Autologous Blood and Marrow Transplant
egistry/International Bone Marrow Transplant Reg-
stry response criteria [18] was retrospectively applied
o posttransplant response. The deﬁnition of complete
esponse (CR) by these standards requires the com-
lete disappearance of myeloma proteins from blood
nd/or urine as determined by routine electrophoresis
nd immunoﬁxation. Patients who did not have a
onoclonal protein on routine electrophoresis but
mmunoﬁxation was not performed were designated
o have had a very good partial response (VGPR).
hemosensitive was deﬁned as a partial response (PR)
r better to the last chemotherapy regimen.
tatistical Analysis
Data was collected until March 2006 to allow for
minimum follow-up of 3 years. Patient characteris-
ics in the 2 groups were compared using the chi-
quared test and the Wilcoxon rank-sum test for con-
inuous data. OS was calculated from transplantation
ntil death from any cause. EFS was calculated from
he day of SCT until myeloma relapse or death from
ny cause. TRM was deﬁned as all nonmyeloma
eaths related to the SCT. Probabilities of OS and
FS were calculated based on the Kaplan-Meier
ethod. Relapse incidence, TRM, and aGVHD and
GVHD were calculated using cumulative incidence
o account for competing risks. Univariate analysis
as performed with the log-rank test to compare sur-
ival between groups. Cox proportional hazard regres-
ion was employed with time-dependent covariates
here appropriate. All P-values are 2 sided and P 
05 was considered statistically signiﬁcant.
To determine if there was a subgroup of patients
ho did worse within the alloSCT group comparisons
ere made for the following factors: sex, type of M-
rotein (IgG or other), stage (based on Durie-Salmon
riteria) [19], 2-microglobulin (3 or 3 mg/L),
hemosensitive prior to SCT, and number of thera-
ies (other than radiation) prior to transplantation.
ESULTS
aseline Characteristics
Both groups were similar in a number of basic
haracteristics pre-SCT, but several important differ-
nces were noted (Table 1). The alloSCT group had a
ounger median age, advanced Durie-Salmon stage,
nd less palliative radiation was given prior to SCT
ompared to the ASCT group. They also had a
horter time from diagnosis to transplant (median: 3.9
onths; range: 1.5-67.0 months versus 5.4 months;
ange: 2.5-68.7 months; P  .01). Characteristics of
lloSCT patients are given in Table 2.
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J. Kuruvilla et al.928esponse Rates
Disease response, routinely assessed at day 100, is
resented in Table 3. Response rate was unevaluable in
number of patients primarily because of early deaths
ut also because of unavailable results. There was no
tatistical difference in response rate at day 100 (P 
12).
S and EFS
At the time of last follow-up, 61 patients remained
live with a median follow-up of 88.4 months range
35.5-208.5 months). There were 28 patients still alive
n the alloSCT group (median follow-up 102.2
onths) and 33 patients in the ASCT group (median
ollow-up 87.7 months). OS of the entire group was
7.1% (95% conﬁdence interval [CI] 39.3-55.0%) at 5
ears and 33.4% (95% CI 24.5-42.3%) at 10 years. OS
or the alloSCT patients was 48.1% (95% CI 37.0-
9.3%) at 5 years and 39.9% (95% CI 27.6-52.2%) at
0 years, whereas the ASCT patients had an OS of
6.2% (95% CI 35.6-56.8%) at 5 years and 30.8%
95% CI 18.8-42.8%) at 10 years (P  .94) (Figure 1).
able 2. Transplant Characteristics In Allogeneic Transplant
ecipients
Characteristic Number of Patients (%)
ype of transplant
Matched sibling 58 (81)
Unrelated donor 14 (19)
VHD prophylaxis
CSPMTX 66 (92)
Other 6 (8)
onor CMV status
Positive 35 (49)
Negative 37 (51)
onor sex
Male 35 (49)
Female 37 (51)
onditioning
Melphalan-based 50 (70)
TBI-based 13 (18)
Other 09 (13)
VHD indicates graft-versus-host disease; CSP, cyclosporine;
MTX, methotrexate; CMV, cytomegalovirus; TBI, total-body
irradiation.
able 3. Disease Response Poststem Cell Transplant
Response
Day 100
ALLO n (%) AUTO n (%)
R/VGPR 27 (38) 21 (25)
R 27 (38) 49 (57)
R/SD/PD 3 (3) 4 (5)
navailable 15 (20) 12 (13)
otal 72 (100) 86 (100)
R indicates complete response; VGPR, very good partial response;
PR, partial response; MR, minimal response; SD, stable disease;
PD, progressive disease. whe EFS for the entire group was 33.1% (95% CI
5.7-40.5%) at 5 years and 22.9% (95% CI 15.5-
0.3%) at 10 years. The alloSCT had EFS of 33.3%
95% CI 22.4-44.2%) at 5 years and 31.4% (95% CI
0.5-42.3%) at 10 years compared to 32.9% (95% CI
2.8-43.0%) and 15.2% (95% CI 5.9-24.5%) for the
SCT group (P  .64) (Figure 2).
Of the 28 patients alive after alloSCT, 21 remain
n continuous remission. Five patients are being
reated for active myeloma and 2 have achieved fur-
her remission post donor lymphocyte infusion (DLI).
or those who underwent alloSCT, EFS and OS were
ot inﬂuenced by any of the analyzed factors. Inter-
stingly, there was a trend for worse OS for those who
ad B2M 3.0 (P  .08). Chemosensitivity prior to
lloSCT was not a statistically signiﬁcant factor (OS
 .48; EFS P  .14), but all 4 patients who had
rogressive disease prior to alloSCT died between 12
nd 42 months post-alloSCT (3 relapse, 1 TRM).
igure 1. Kaplan-Meier estimate of overall survival for patients
ho underwent AlloSCT () and ASCT () (P  .94).
igure 2. Kaplan-Meier estimate of event-free survival for patients
ho underwent AlloSCT () and ASCT () (P  .64).
P
u
a
s
i
l
t
i
G
d
I
a
(
(
d
i
O
d
.
D
n
O
r
d
r
d
O
e
r
h
T
h
d
P
1
g
(
r
i
t
o
(
t
A
d
r
s
D
c
f
l
r
e
d
a
a
t
p
i
t
d
l
p
c
e
s
r
d
s
c
F
m
c
v
F
h
Long-Term Outcome of Myeloablative AlloSCT for Multiple Myeloma 929atients who received stem cells from a volunteer
nrelated donor had signiﬁcantly worse EFS (P .05)
nd OS (P  .05) compared to those who received
tem cell from a related donor. To eliminate the
mpact of patients who received unrelated donor al-
oSCT on outcome, the ASCT group was compared
o related alloSCT. There was no statistical difference
n EFS (P  .34) and OS (P  .53).
VHD
Fifty-two of the 72 patients in the alloSCT arm
eveloped grade II-IV aGVHD of whom 23 had grade
II-IV. The cumulative incidence of grade II-IV
GVHD was 72% at 1 year. cGVHD was absent in 13
18%), present in 48 (67%), and unevaluable in 11
15%) because of early death. The cumulative inci-
ence of cGVHD was 68% at 2 years. There was no
nﬂuence of either aGVHD or cGVHD on EFS or
S. The risk of relapse was reduced in those who
eveloped aGVHD (P  .02) but not cGVHD (P 
23).
LI
DLI were given to 14 patients. Five patients did
ot develop GVHD and demonstrated no response.
f the 5 patients, 3 have died of myeloma and 2
emain alive on antimyeloma therapy. Nine patients
eveloped GVHD but only 5 of these had a disease
esponse. Of the 4 who have not responded, 3 died of
isease and 1 remains alive on antimyleoma therapy.
f the 5 who responded, 2 remain alive without dis-
ase 5 and 8 years after their last dose of DLI. The
emaining 3 had partial responses lasting 1 year and
ave all died of disease.
RM, Relapse, and Deaths
Cumulative incidence of TRM at 1 year was
igure 3. Cumulative incidence of treatment related mortality:
ortality at 1 year was higher in patients who underwent AlloSCT
ompared to ASCT, but the difference was not signiﬁcant (22%
ersus 14%; P  .21).igher in the alloSCT group, although the difference bid not reach statistical signiﬁcance (22% versus 14%,
 .21) (Figure 3). Cumulative incidence of relapse at
0 years was not statistically different between the
roups, although it was higher in the ASCT group
60% versus 41%, P  .10) (Figure 4). There were 8
elapses that occurred 5-years posttransplantation; 6
n the ASCT group, and 1 in the alloSCT group. In
he alloSCT group 44 patients have died. The causes
f death were: relapsed disease (n  22), GVHD
n  13), regimen-related toxicity (n  5), infec-
ious causes (n  2), and other causes (n  2). In the
SCT group 53 patients have died. The causes of
eath were: relapsed disease (n  34), regimen-
elated toxicity (n  13), infection (n  2), and
econd malignancies (n  4).
ISCUSSION
This report describes one of the largest single-
enter experiences of myeloablative allogeneic SCT
or patients with multiple myeloma with median fol-
ow-up of 8 years for surviving patients. The major
ationale of offering alloSCT is the potential GVM
ffect. A reduction in relapse was seen in patients who
eveloped aGVHD but not cGVHD. Neither
GVHD nor cGVHD had a beneﬁcial effect on EFS
nd OS; however, DLI was effective in 5 of 14 pa-
ients, with 2 patients in sustained remission. Larger
atient numbers may have demonstrated a positive
mpact of GVHD on survival [20].
The group of patients who received myeloabla-
ive alloSCT was compared to the group who un-
erwent ASCT. Such a comparison has signiﬁcant
imitations because of selection bias in assigning
atients to either transplant modality, and direct
omparison may not be appropriate. Regardless,
ven with the most carefully constructed transplant
tudies, there will remain problems with patient
ecruitment, crossover, and fallout resulting in a
egree of clouding of the interpretation of the re-
ults. Despite these limitations, for this study, the
omparison was carried out to help illustrate the
igure 4. Cumulative incidence of relapse: relapse at 10 years was
igher in patients who underwent ASCT compared to AlloSCT,
ut the difference was not signiﬁcant (41% versus 60%; P  .10).
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J. Kuruvilla et al.930ssues surrounding myeloablative alloSCT for my-
loma. Despite a strategy minimizing pretreatment
nd early transplantation resulting in a relatively
ow TRM, a clear OS or EFS advantage of myeloa-
lative alloSCT compared to ASCT could not be
emonstrated. After 5 years, more relapses occurred
n the ASCT group compared to the myeloablative
lloSCT group (6 versus 1), but this did not result in
statistically signiﬁcant difference in EFS or OS.
TRM appeared higher in the myeloablative al-
oSCT arm, but this did not reach statistical signiﬁ-
ance. The TRM for patients undergoing ASCT is
igher than what would be currently expected, but is
imilar to that reported by other centers during this
ra [11]. The TRM in our myeloablative alloSCT
ohort may be better than other reports of fully my-
loablative alloSCT because of the minimal pretreat-
ent, the relatively short time from diagnosis to SCT,
onsistent care at a single center, and the fact that
adiation for transplant conditioning was used only for
nrelated or mismatched donor transplants. Similar
mprovement in TRM for patients undergoing my-
loablative alloSCT for has been reported [10,21].
To harness the GVM effect but reduce the TRM,
educed-intensity conditioning (RIC) alloSCT is be-
ng investigated. These transplants can be offered to
lder patients as well as those with more comorbidi-
ies. The Seattle group has reported the results of 52
atients in which an ASCT utilizing melphalan 200
g/m2 was followed by TBI of 200 cGy and unma-
ipulated PBSCs from a matched sibling donor. The
00-day TRM was 0% and the OS was 78% at a short
edian follow-up of 18 months. Other groups have
hown similar promising preliminary results [22,23].
he EBMT registry reviewed of 229 patients under-
oing RIC alloSCT [20]. A respectable TRM of 22%
as reported, but 3-year OS and progression-free sur-
ival (PFS) were disappointing at 41% and 22%. Im-
ortantly, this study demonstrated that development
f cGVHD was associated with better OS and PFS. A
ecently published multicenter study demonstrated
he superiority of nonmyeloablative alloSCT com-
ared to tandem ASCT [24]. In this publication,
GVHD did not have an inﬂuence clinical response.
espite these promising results, the role of RIC
lloSCT for high-risk myeloma remains controversial.
he Intergroupe Francophone du Myélome per-
ormed a trial for patients with high-risk myeloma
ho underwent biologic randomization comparing
andem ASCT to ASCT followed by RIC alloSCT
25]. This trial did not demonstrate superiority of the
IC alloSCT strategy, although concerns were raise
egarding the possible T cell-depleting effects of an-
ithymocyte globulin (ATG) (Imtix; Genzyme, Cam-
ridge, MA), used as a part of the conditioning for the
lloSCT arm, resulting in reduction of the GVM
ffects. Whether a fully myeloablative alloSCT wouldave an advantage in reducing the relapse rate for
atients with high-risk myeloma compared to ASCT
ollowed by RIC alloSCT remains speculative [26].
Modern prognostic factors are being assessed par-
icularly related to cytogenetic aberrations. Recent
eports indicate that patients derive less beneﬁt from
SCT if their myeloma has adverse cytogenetic
hanges [27,28]. Similar concerns have been raised for
atients undergoing RIC AlloSCT [25,29]. Unfortu-
ately, cytogenetic or ﬂuorescence in situ hybridiza-
ion (FISH) studies for common prognostic aberra-
ions were not available in our patients because they
ere diagnosed prior to the routine availability of
hese tests for myeloma. Within these limitations it is
ncertain if some of the patients have clearly beneﬁted
rom a myeloablative alloSCT.
In conclusion, the beneﬁts of the GVM effects are
imited to a minority of patients. Although a number
f patients remain alive without disease 10 years
ostmyeloablative alloSCT, there are also patients
live after a similar length of time post-ASCT. Pa-
ients who are known to respond poorly with standard
reatment strategies including ASCT may be consid-
red for alloSCT, possibly myeloablative, in the hopes
hat a beneﬁt can be derived despite the morbidity.
egardless, at this time myeloablative alloSCT should
ot be considered standard treatment and requires
urther investigation in the setting of prospective clin-
cal trials.
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